Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.

Bianciardi P, Brovida C, Valente M, Aresu L, Cavicchioli L, Vischer C, Giroud L, Castagnaro M.

Toxicol Pathol. 2009 Oct;37(6):770-5. doi: 10.1177/0192623309344088. Epub 2009 Aug 18.

PMID:
19690151
2.

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.

Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE.

Parasit Vectors. 2015 May 28;8:289. doi: 10.1186/s13071-015-0896-0.

3.

Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Mateo M, Maynard L, Vischer C, Bianciardi P, Miró G.

Parasitol Res. 2009 Jul;105(1):155-62. doi: 10.1007/s00436-009-1375-3. Epub 2009 Feb 24.

PMID:
19238439
4.

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.

Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.

Acta Trop. 2007 Jul;103(1):33-40. Epub 2007 May 18.

PMID:
17586452
5.

Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.

Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P.

Vet Dermatol. 2009 Oct;20(5-6):397-404. doi: 10.1111/j.1365-3164.2009.00824.x.

PMID:
20178476
6.

Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.

de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A.

J Antimicrob Chemother. 2015 Dec;70(12):3283-90. doi: 10.1093/jac/dkv254. Epub 2015 Sep 7.

PMID:
26346991
7.

Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.

Ikeda-Garcia FA, Lopes RS, Ciarlini PC, Marques FJ, Lima VM, Perri SH, Feitosa MM.

Res Vet Sci. 2007 Aug;83(1):105-8. Epub 2006 Dec 5.

PMID:
17150234
8.

Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.

de Moura FJ, Leal PP, de Souza Furtado R, Muniz-Junqueira MI, Veiga JP.

Toxicology. 2008 Jan 14;243(1-2):66-74. Epub 2007 Oct 7.

PMID:
18022309
9.

Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.

Valladares JE, Riera C, Alberola J, Gállego M, Portús M, Cristòfol C, Franquelo C, Arboix M.

Vet Parasitol. 1998 Feb 15;75(1):33-40.

PMID:
9566092
10.

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.

Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Pérez M, Nicholls RS, Gore Saravia N.

J Infect Dis. 2012 Feb 15;205(4):684-92. doi: 10.1093/infdis/jir816. Epub 2012 Jan 11.

11.

Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.

Torres M, Bardagí M, Roura X, Zanna G, Ravera I, Ferrer L.

Vet J. 2011 Jun;188(3):346-51. doi: 10.1016/j.tvjl.2010.05.025. Epub 2010 Jul 1.

PMID:
20594876
12.

[Canine leishmaniasis: evolution of the chemotherapeutic protocols].

Oliva G, Foglia Manzillo V, Pagano A.

Parassitologia. 2004 Jun;46(1-2):231-4. Review. Italian.

PMID:
15305724
13.

The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol.

Cortese L, Pelagalli A, Piantedosi D, Mastellone V, Di Loria A, Lombardi P, Ciaramella P, Avallone L.

Vet J. 2008 Sep;177(3):405-10. Epub 2007 Jul 12.

PMID:
17629526
14.

Embryotoxicity of meglumine antimoniate in the rat.

Paumgartten FJ, Chahoud I.

Reprod Toxicol. 2001 May-Jun;15(3):327-31.

PMID:
11390176
15.

In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum.

Pujals G, Suñé-Negre JM, Pérez P, García E, Portus M, Tico JR, Miñarro M, Carrió J.

Parasitol Res. 2008 May;102(6):1243-7. doi: 10.1007/s00436-008-0901-z. Epub 2008 Feb 17.

PMID:
18278586
16.

Pentavalent antimonial nephrotoxicity in the rat.

Veiga JP, Khanam R, Rosa TT, Junqueira Júnior LF, Brant PC, Raick AN, Friedman H, Marsden PD.

Rev Inst Med Trop Sao Paulo. 1990 Jul-Aug;32(4):304-9.

PMID:
2101525
17.
18.

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.

Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.

AIDS. 1999 Jun 18;13(9):1063-9.

PMID:
10397536
19.

Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat.

Miranda ES, Miekeley N, De-Carvalho RR, Paumgartten FJ.

Reprod Toxicol. 2006 Apr;21(3):292-300. Epub 2005 Nov 3.

PMID:
16271447
20.

[Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].

Garcia Bustos MF, Barrio A, Parodi C, Beckar J, Moreno S, Basombrio MA.

Medicina (B Aires). 2014;74(5):371-7. Spanish.

Supplemental Content

Support Center